STOCKHOLM, 25 april, 2018 – The 2017 Annual report of Promore Pharma AB (publ) is now available on the company website, promorepharma.com.
Printed copies can be ordered from Promore Pharma AB, Karolinska Institutet Science Park, Fogdevreten 2, SE-171 65 Solna, or by e-mail info@promorepharma.com.
For additional information, please contact
Jonas Ekblom, VD
Tel: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Jenni Björnulfson, CFO
Tel: [+46] 708 55 38 05
E-mail: jenni.bjornulfson@promorepharma.com
This information is information that Promore Pharma AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 17.15 CET on 25 April 2018.
Promore Pharma in brief:
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma’s two projects, PXL01 and LL-37, are in late stage clinical phase. PXL01, that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical Phase III-studies in patients undergoing tendon repair surgery in the hand. LL-37 is being prepared for a clinical Phase IIb study in patients with venous leg ulcers. The product candidates can also be deployed for other indications, such as preventing dermal scarring and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North with Redeye AB as Certified Adviser.